The global homatropine hydrobromide market is expected to grow at a significant CAGR during the forecast period (2021-2027). Homatropine hydrobromide is an anticholinergic medication that causes mydriasis and cycloplegia, as well as other anticholinergic effects. Other effects of structurally similar atropine that might apply to homatropine include secretion inhibition, tachycardia, smooth muscle relaxation, and central neurological effects such as excitement.

Homatropine hydrobromide is a competitive muscarinic receptor antagonist that replaces the acetyl group of acetylcholine with a bulky aromatic group. It's thought to work similarly to atropine, causing parasympatholytic effects. Homatropine inhibits the reaction of the iris sphincter muscle, causing the pupil to become unresponsive to light upon dilatation or mydriasis, via inhibiting muscarinic receptors and cholinergic signalling pathways. It also prevents cholinergic activation of the ciliary body's accommodating muscle.

Homatropine relaxes the muscles in the iris of the eye. The pupil dilates or expands when these muscles are relaxed. Ophthalmic homatropine is used to treat a condition known as uveitis. During an eye checkup, ophthalmic homatropine is frequently used to dilate the pupil or to relieve pressure inside the eye after surgery. This medication is used to treat some eye problems before and during eye tests (such as refraction), as well as before and during certain eye surgeries (e.g., uveitis). Homatropine hydrobromide acts via dilation of the pupil (dilating it).

According to IOVS Arvo Journal, Age-related cataract (ARC) is still the most common cause of vision loss globally, particularly in China, which has one-fifth of the world's population. Surgery is now the sole effective therapy for cataracts, although it is still prohibitively expensive in impoverished nations. A cataract is a major socioeconomic burden all around the world. The overall cost of ARC in the United States, according to the US government, is $5 to $6 billion each year. As the elderly population grows, so does the visual impairment caused by ARC and the resulting economical load. Therefore, the rising incidences of cataracts and other visual disorders requiring surgery in the geriatric population are expected to drive the market growth of the global Homatropine hydrobromide market.

Furthermore, C2 Pharma (C2P), a Luxembourg-based phytochemical and chemical-pharmaceutical production and distribution company, is continuing to expand its API and botanical extracts product line. The authorization of Homatropine hydrobromide was the most recent contribution in 2020 that will propel the market growth.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type 

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Centroflora, Hubei Biocause Pharmaceutical, Pioneer Agro Industries, Resonance Laboratories, Saurav Chemicals, Vital Laboratories.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Homatropine Hydrobromide Market by Segments

By Type

• Injectable
• Tablets
• Drops

Global Homatropine Hydrobromide Market by Region